Deals
Bristol-Myers Will Divest Celgene Blockbuster to Close Deal
- Drugmaker pushes back close target to late 2019, early 2020
- Otezla is a large, growing product; Bristol-Myers shares fall
This article is for subscribers only.
Bristol-Myers Squibb Co. agreed to divest one of Celgene Corp.’s most lucrative drugs in order to close their planned $74 billion merger.
Under an agreement with the Federal Trade Commission, Bristol-Myers will sell off the psoriasis pill Otezla to appease antitrust regulators’ concerns, the company said in a statement.